Endonovo Therapeutics, Inc.
ENDV · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | -0.00 |
| FCF Yield | 46.19% | 5.07% | -27.09% | -105.69% |
| EV / EBITDA | -7.53 | 1.07 | -0.59 | -5.30 |
| Quality | ||||
| ROIC | 7.86% | 17.22% | 13.08% | 26.15% |
| Gross Margin | -6,125.64% | -366.87% | 92.62% | 79.50% |
| Cash Conversion Ratio | -0.04 | 0.02 | 0.04 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -57.98% | 24.25% | -6.54% | -38.23% |
| Free Cash Flow Growth | -17.54% | 117.95% | 31.19% | -33.04% |
| Safety | ||||
| Net Debt / EBITDA | -7.30 | 0.80 | -0.43 | -4.68 |
| Interest Coverage | -1.26 | -2.28 | -2.47 | -2.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,000.71 | -601.84 | -32,209.51 | -16,030.88 |